🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase III

Oncology programs at Phase III — ClinicalTrials.gov pipeline intelligence.

Programs
1,266

Quick answer

Oncology Phase III programs: NovaPharmaNews indexes 1,266 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 21 of 27

  1. Subxiphoid uniportal VATS

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Neoplasms

    phase 3 other completed

    1 trial

  2. Subxiphoid uniportal VATS

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mediastinal Neoplasms

    phase 3 other active

    1 trial

  3. Sunitinib AqVida 12,5 mg Hartkapseln, QINLOCK 50 mg tablets

    Lacuna Pharma Pty Ltd

    Patients with Advanced Gastrointestinal Stromal Tumors

    phase 3 small molecule active

    1 trial

  4. Suprefact Depot 9,45 mg implantat, Pamorelin 11,25 mg, poeder en oplosmiddel voor suspensie voor injectie, met verlengde afgifte., Pamorelin 22,5 mg, poeder en oplosmiddel voor suspensie voor injectie, met verlengde afgifte., Pamorelin 3,75 mg, poeder en oplosmiddel voor suspensie voor injectie, met verlengde afgifte., Eligard 45 mg poeder en oplosmiddel voor oplossing voor injectie, LEUPRORELIN ACETATE, CAMCEVI 42 mg prolonged-release suspension for injection, Gonapeptyl Depot 3,75 mg poeder en oplosmiddel

    Disc Medicine

    low-volume metastatic castration-sensitive prostate cancer

    phase 3 small molecule active

    1 trial

  5. Surgery and HIPEC with Lobaplatin

    Universal Integrated

    Colorectal Neoplasms

    phase 3 other active

    1 trial

  6. Surovatamig

    AstraZeneca

    Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV

    phase 3 small molecule active

    1 trial

  7. Sutent 12.5 mg hard capsules, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PAZOPANIB , Sutent 25 mg hard capsules

    Incyte

    Locally advanced/metastatic renal cell carcinoma

    phase 3 small molecule active

    1 trial

  8. Systematic oral health education

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Malignant Tumor of Head and/or Neck

    phase 3 other completed

    1 trial

  9. TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, Datopotamab deruxtecan

    AstraZeneca AB

    Epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  10. TAGRISSO 80 mg film-coated tablets, CARBOPLATIN, CISPLATIN, PEMETREXED

    AstraZeneca AB

    Patients with locally-advanced or metastatic EGFRm (Ex19del and/or L858R) Non-Small Cell Lung Cancer.

    phase 3 small molecule active

    1 trial

  11. TAGRISSO 80 mg film-coated tablets, INFLIXIMAB, TAGRISSO 40 mg film-coated tablets, MYCOPHENOLATE MOFETIL, GLUCOSE, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Main cohort: Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer Osimertinib cohort: Open-label, Single arm for patients with unresected stage I/II, lymph done negative NSCLC harboring a sensitizing EGFR mutation

    phase 3 small molecule active

    1 trial

  12. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO

    AstraZeneca AB

    Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, either alone or in combination with other EGFR mutations, as detected by cobas® EGFR Mutation Test v2 (Roche Diagnostics) and whose disease has not progressed following definitive platinum-based chemoradiation.

    phase 3 small molecule active

    1 trial

  13. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO

    AstraZeneca AB

    Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following complete tumour resection with or without adjuvant chemotherapy

    phase 3 small molecule active

    1 trial

  14. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, Placebo

    AstraZeneca AB

    Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (Ex19del, L858R), following complete tumour resection.

    phase 3 small molecule active

    1 trial

  15. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, placebo capsule G065, placebo capsule G040, JNJ-61186372, JNJ-73841937, JNJ-73841937-ZCY Placebo Oral Film-Coated Tablet

    Janssen-Cilag International N.V.

    EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  16. TAK-788

    Takeda

    Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  17. TALAZOPARIB, TALAZOPARIB, TALAZOPARIB, Xtandi - 40 mg soft capsules, TALAZOPARIB

    Pfizer Australia Pty Ltd

    Metastatic Castration-resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  18. TAMOXIFEN , EXEMESTANE , ANASTROZOLE , LETROZOLE , Verzenios 50 mg film-coated tablets

    Eli Lilly Co.

    Breast Cancer

    phase 3 small molecule active

    1 trial

  19. TAMOXIFEN, LETROZOLE, ANASTROZOLE, FULVESTRANT, LEUPRORELIN, OXYBUTYNIN, GOSERELIN, VENLAFAXINE, LEUPRORELIN, GOSERELIN, EXEMESTANE, VENLAFAXINE

    Shanghai Reinovax Biologics Co.,LTD

    Breast cancer

    phase 3 small molecule active

    1 trial

  20. TAP-144-SR(6M)

    Takeda

    Premenopausal Breast Cancer

    phase 3 small molecule completed

    1 trial

  21. TAP-144-SR(6M)

    Takeda

    Prostate Cancer

    phase 3 small molecule completed

    1 trial

  22. TARA-002

    Protara Therapeutics

    Bladder (Urothelial, Transitional Cell) Cancer

    phase 3 small molecule active

    1 trial

  23. TAXOL 6 mg/ml, concentrato per soluzione per infusione

    Lacuna Pharma Pty Ltd

    Recurrent or Metastatic HER2 Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  24. TCM

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  25. TOCILIZUMAB, Tarlatamab, DEXAMETHASONE, Placebo for Tarlatamab (AMG-757), PARACETAMOL , ELECTROLYTES , PREDNISOLONE , Tarlatamab, VASOPRESSIN (ARGIPRESSIN) , SILTUXIMAB

    Amgen

    Limited-Stage Small-Cell Lung Cancer (LS SCLC)

    phase 3 small molecule active

    1 trial

  26. TOOKAD 183 mg powder for solution for injection, PADELIPORFIN

    STEBA Biotech S.A

    Low Grade Upper Tract Urothelial Cancer

    phase 3 small molecule active

    1 trial

  27. TOPOTECAN , DOSTARLIMAB , BEVACIZUMAB , PACLITAXEL , NIRAPARIB , DOXORUBICIN , GEMCITABINE

    Fondazione Telethon ETS

    Recurrent ovarian, fallopian tube or primary peritoneal cancer

    phase 3 small molecule active

    1 trial

  28. TOPOTECAN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE, PACLITAXEL, KEYTRUDA 25 mg/mL concentrate for solution for infusion, NEMVALEUKIN ALFA, GEMCITABINE HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

    Wuhan Createrna Science and Technology Co., Ltd

    Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    phase 3 small molecule active

    1 trial

  29. TOPOTECAN, TOPOTECAN, IRINOTECAN, TOPOTECAN, lurbinectedin, TOPOTECAN

    Lacuna Pharma Pty Ltd

    Small Cell Lung Cancer (SCLC)

    phase 3 small molecule active

    1 trial

  30. TOPOTECAN, TOPOTECAN, Ifinatamab deruxtecan

    Daiichi Sankyo

    Small Cell Lung Cancer (SCLC)

    phase 3 small molecule active

    1 trial

  31. TOPOTECANE ACCORD 1 mg/ml, solution à diluer pour perfusion, TOPOTECANE ACCORD 1 mg/ml, solution à diluer pour perfusion

    GlaxoSmithKline

    Neoplasms, Lung

    phase 3 small molecule active

    1 trial

  32. TPST-1120

    Tempest Therapeutics

    Hepatocellular Carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  33. TRASTUZUMAB, Tislelizumab, Oxaliplatin 5 mg/ml concentrate for solution for infusion, LOPERAMIDE, JZP598, CAPECITABINE

    Jazz Pharmaceuticals Ireland Limited

    Gastroesophageal Adenocarcinoma (GEA)

    phase 3 small molecule active

    1 trial

  34. TRUQAP 160 mg film-coated tablets, Fulvestrant Dr. Reddy’s 250 mg Solution For Injection in Pre-Filled Syringe, RLY-2608, Fulvestrant EVER Pharma 250 mg solution for injection in pre-filled syringe, Fulvestrant Dr. Reddys 250 mg solución inyectable en jeringa precargada EFG, TRUQAP 200 mg film-coated tablets

    Relay Therapeutics

    PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer

    phase 3 small molecule active

    1 trial

  35. TRUQAP 160 mg film-coated tablets, TRUQAP 200 mg film-coated tablets

    AstraZeneca

    HR+ / HER2- advanced breast cancer

    phase 3 small molecule active

    1 trial

  36. TUCATINIB, CAPECITABINE, TUCATINIB, RO7771950, RO7771950, TRASTUZUMAB, CAPECITABINE, TRASTUZUMAB

    Hoffmann-La Roche

    Pretreated Unresectable Locally Advanced or Metastatic human epidermal growth factor receptor 2 (HER2)-Positive Breast Cancer, with or without Central Nervous System (CNS) Metastases

    phase 3 small molecule active

    1 trial

  37. Tamoxifen

    Pfizer

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  38. Tamoxifen

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer Female

    phase 3 small molecule active

    1 trial

  39. Tamoxifen

    International Peace Maternity and Child Health Hospital

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  40. Tamoxifen Viatris 20 mg tabletter.

    The George Institute

    Breast Cancer

    phase 3 small molecule active

    1 trial

  41. Targocid 400mg powder for solution for injection/infusion or oral solution, Targocid 400mg powder for solution for injection/infusion or oral solution, Targocid 400mg powder for solution for injection/infusion or oral solution, Targocid 400mg powder for solution for injection/infusion or oral solution

    AXIM BIOTECHNOLOGIES, INC.

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  42. Tarlatamab

    Amgen

    Small Cell Lung Cancer (SCLC)

    phase 3 small molecule active

    1 trial

  43. Tarlatamab

    Amgen

    Extensive-Stage Small-Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  44. Tarlatamab, OXALIPLATINE VIATRIS 5 mg/ml, poudre pour solution pour perfusion, Dacarbazine "Lipomed", Tecentriq 1 200 mg concentrate for solution for infusion, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion, Temozolomide 100 mg hard capsules, OPDIVO 10 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Topotecan Accord Healthcare 4mg Powder for Concentrate for Solution for Infusion, IRINOTECAN VIATRIS 20 mg/ml, solution à diluer pour per

    CERO THERAPEUTICS HOLDINGS, INC.

    Advanced pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas (NECs)

    phase 3 small molecule active

    1 trial

  45. Taselisib

    Hoffmann-La Roche

    Breast Cancer

    phase 3 small molecule terminated

    1 trial

  46. Tasigna 200 mg hard capsules, DASATINIB, IMATINIB, DASATINIB, ASCIMINIB HYDROCHLORIDE, NILOTINIB, IMATINIB, DASATINIB, NILOTINIB, BOSUTINIB, BOSUTINIB, Tasigna 150 mg hard capsules, DASATINIB, Tasigna 150 mg hard capsules, Tasigna 150 mg hard capsules, IMATINIB, Tasigna 150 mg hard capsules, Tasigna 200 mg hard capsules, Tasigna 200 mg hard capsules, Tasigna 200 mg hard capsules, Tasigna 150 mg hard capsules, Tasigna 200 mg hard capsules, ASCIMINIB HYDROCHLORIDE, Tasigna 200 mg hard capsules

    Novartis Pharmaceuticals

    chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

    phase 3 small molecule active

    1 trial

  47. Tasisulam-sodium

    Eli Lilly and Company

    Melanoma

    phase 3 small molecule terminated

    1 trial

  48. Taxane

    Hoffmann-La Roche

    Gastric Cancer

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

How many oncology Phase III programs exist?

1,266 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.